The This study, coordinated in Portugal by researcher Helena Florindo from the Faculty of Pharmacy of the University of Lisbon, was published today in the scientific journal britâsingular Natural Nanotechnology.
The experimental vaccine was used in melanoma mice. metastasis, a type of cancer where patients respond poorly immunotherapy (treatment in which they are enabled system cells immune to fight the tumor).
In this case, the team of Helena Florindo, in partnership with a working group of the University of Tel Avivfrom Israel created a vaccine that could "train" the system immune react with cellular biological markers tumor and destroy only these cells, avoiding adverse effects on cells or organs healthy (as with chemotherapy).
The scientist explained to Lusa that the vaccine has simple sugar in its composition (mannose) and a sequence of two peptides (fractions protein) that is present in melanoma cells.
The vaccine does not to act in the tumor but in the cells dendritewhich are part of the system immune, which protects the body against invading agents.
According to Elena Florindo, these cells "will recognize the vaccine and to doit is visible "to other system cells immune, the lymphocytes T, which play a key role in cellular self-destruction carcinogen.
In the background, the cells dendrite "will show" T cells that "are against these peptides [inoculados na vacina] they have to react, "said the researcher at the University of Lisbon.
In your experiment with mice with melanoma metastasis, the team of scientists found that the vaccine only works in practice if a drug is administered in parallel, theibrutinib& # 39 ;, which will lock the function of cells immunosuppressive, cells that inhibit the body's immune response and that researchers detected in rodent tumors in association with decreased lymphocytes T.e.
Rodents who received three doses of vaccine – one dose a week – as a treatment in combination with immunotherapy for more aggressive melanoma and the drug & # 39;ibrutinibRemained alive in 70% of cases after two months.
In contrast, mice that were subjected only immunotherapy combined with the drug survived in 20% of the situations simultaneously and those vaccinated and treated simultaneousâneo with immunotherapy remained alive in only 7% of cases.
The animals that did not receive treatment died after 28 days.
Before testing the therapeutic effect of the vaccine on diseased mice, scientists checked its effect prophylactic, when rodents were vaccinated before developing aggressive cancer: half of the animals survived "long" after also receiving three doses of the experimental vaccine, combined with immunotherapy against melanoma metastasis.
In a next step, the scientific team, which plans to patent the vaccine and produce it on an industrial scale to test it on animals and then humans, will study the implications of the vaccine on foot cancer.nonsensewhose patients have approx survival "very low".
Always be the first to know.
Follow the website of choice for the second consecutive year Consumer Choice.
Download our free App.